IMV (IMVIF) EBIT: $-38.47 Mil (TTM As of Dec. 2022)


IMVIF IMV Inc IMVIF
12 GF Score
Price $0.00
View Full Analysis

What is IMV EBIT?

IMV IMVIF -99.95% 12 EBIT is $-38.47 Mil as of Dec. 2022. GuruFocus rates IMVIF with a GF Score™ of 12/100.

IMV's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2022 was $-8.59 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2022 was $-38.47 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. IMV's annualized ROC % for the quarter that ended in Dec. 2022 was -813.83%. IMV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2022 was -897.01%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

IMV  (OTCPK:IMVIF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

IMV's annualized ROC % for the quarter that ended in Dec. 2022 is calculated as:

ROC % (Q: Dec. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2022 ) + Invested Capital (Q: Dec. 2022 ))/ count )
=-34.36 * ( 1 - 0% )/( (4.301 + 4.143)/ 2 )
=-34.36/4.222
=-813.83 %

where

Invested Capital(Q: Sep. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=32.272 - 9.726 - ( 21.738 - max(0, 10.126 - 28.371+21.738))
=4.301

Invested Capital(Q: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=31.348 - 9.037 - ( 21.223 - max(0, 9.42 - 27.588+21.223))
=4.143

Note: The Operating Income data used here is four times the quarterly (Dec. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

IMV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2022 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2022 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2022  Q: Dec. 2022
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-34.36/( ( (3.901 + max(-4.175, 0)) + (3.76 + max(-3.886, 0)) )/ 2 )
=-34.36/( ( 3.901 + 3.76 )/ 2 )
=-34.36/3.8305
=-897.01 %

where Working Capital is:

Working Capital(Q: Sep. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.752 + 0 + 4.85) - (9.726 + 0 + 0.050999999999998)
=-4.175

Working Capital(Q: Dec. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.727 + 0 + 4.44) - (9.037 + 0 + 0.016)
=-3.886

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2022) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

IMV's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2022 )
=-38.468/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IMV EBIT Related Terms

IMV EBIT Historical Data

* Premium members only.

The historical data trend for IMV's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IMV EBIT Chart

IMV Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.09 -20.00 -26.03 -35.68 -38.49

IMV Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.27 -10.22 -9.98 -9.68 -8.59

IMVIF vs RGTPQ, QBIO, RGIN: EBIT Comparison

For the Biotechnology subindustry, IMV's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IMV EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IMV's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where IMV's EV-to-EBIT falls into.


IMVIF
12GF Score
IMV Inc IMVIF
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IMV EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-38.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-38.47 Mil mean?
IMV (IMVIF) has a EBIT of $-38.47 Mil as of Dec. 2022. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on IMV.
Is IMV's EBIT too high?
IMV's current EBIT is $-38.47 Mil. Overall, IMV has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does IMV's EBIT compare to RGTPQ and QBIO?
IMV's EBIT of $-38.47 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on IMV. IMV's current EBIT is $-38.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IMV stock overvalued right now?
IMV (IMVIF) has a current EBIT of $-38.47 Mil. The current EBIT is $-38.47 Mil. IMV's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For IMV (IMVIF), the current EBIT is $-38.47 Mil as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IMV Business Description

Address 130 Eileen Stubbs Avenue, Suite 19, Dartmouth, NS, CAN, B3B 2C4
IMV Inc is a clinical-stage biopharmaceutical company. The company is engaged in making immunotherapies more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. Its proprietary drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system.
12GF Score

Get the complete analysis for IMVIF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price